source
- Eli Lilly partners with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseasesEli Lilly announced a collaboration with Boston-based Amplitude Therapeutics, a company that emerged from Lilly’s Gateway Labs incubator. The partnership will focus on developing trans-amplifying…
- Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety eventRegeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis. The decision…